Business of Biotech Shorts

  1. Ep. 255, Chapter 3: Biotech Investors' Pet Peeves with Yaniv Sneor 7/11/2025

    Sneor criticizes "spray and pray" pitches that lack personalization and don't align with the group's specific investment criteria, as well as "scientific pitches" that resemble a poster presentation, rather than a compelling financial story focused on the exit strategy and potential returns. He also cautions that familial relationships can compromise business accountability. Mid Atlantic Bio Angels offers guidance and network access, and they are drawn to opportunities with orphan drug designations that offer potential for expanded indications, or areas so attractive to larger pharma/device companies that early acquisition is likely, providing an efficient path to exit for investors.

  2. Ep. 255, Chapter 2: Hard Questions Investors Ask with Yaniv Sneor 7/11/2025

    Sneor details Mid Atlantic Bio Angels’ considerations when deliberating whether to invest in a biotech startup. The group prioritizes understanding how each biotech plans to monetize its opportunity and achieve a successful exit within five to seven years — looking for a clear path, potential acquirers, and comparable deals — so commercial mindset is as important as scientific prowess. MAB Angels prefers to participate in smaller, syndicated investment rounds of $0.25-$1 million, which allow companies to maintain control and provide consistent progress for investors. Sneor notes that the inherent maturity of biotech companies driven by rigorous data generation and regulatory requirements translates to higher quality investment opportunities.

  3. Ep. 255, Chapter 1: Yaniv Sneor, Mid Atlantic Bio Angels 7/11/2025

    Life Science Leader Chief Editor Ben Comer interviews Yaniv Sneor, co-founder of Mid Atlantic Bio Angels, an angel investor group specializing in life sciences. Sneor and two partners founded the company in 2012 to address the need for specific expertise in diligencing complex life science opportunities. In the past 13 years, the group has attracted an intelligent and engaged membership as well as evolved to an internal fund model. MAB Angels screens more than 100 applications monthly via a diligence process that involves initial gating questions, internal discussions, and a multi-day open voting system with mandatory rationale statements.

  4. Ep. 254, Chapter 4: LNP Progress & Regulation with Michelle Werner 7/11/2025

    Alltrna's lead candidate for genetic diseases utilizes a lipid nanoparticle (LNP) for liver delivery and is currently in IND-enabling studies. LNPs being well-characterized and commercially available allows Alltrna to focus on the novel tRNA payload's safety and efficacy, rather than delivery. Alltrna also is engaging with health authorities to pave the way for its basket trial strategy, which aligns with regulators' stated interest in "many diseases at a time" approaches to address the vast unmet need. Moving forward, Werner says Alltrna's main challenge is transitioning from a research-focused company to one equally weighted in R&D, building clinical capabilities, and securing capital to advance its technology.

  5. Ep. 254, Chapter 3: What's A Stop Codon Disease? With Michelle Werner 7/11/2025

    Welch and Werner discuss Alltrna's patient-first mindset and its practical implications for early-stage rare disease companies. Werner goes on to define the concept of a "stop codon disease" as a reclassification for patients with genetic diseases stemming from a premature termination codon (nonsense mutation). This reclassification, affecting approximately 10% of genetic diagnoses, could allow a single engineered tRNA therapy to address thousands of different life-threatening conditions, offering a universal solution instead of a disease-by-disease approach. Alltrna leverages AI and machine learning to navigate the vast combinatorial space of tRNA designs, optimizing their sequence and chemical modifications for enhanced activity and stability.

  6. Ep. 254, Chapter 2: Why tRNA? With Michelle Werner 7/11/2025

    Alltrna's tRNA technology offers unprecedented ability to universally restore protein function across diverse disease models, regardless of affected gene, protein, or mutation location. For investors, Werner emphasizes the immense unmet need in genetic diseases, explaining how tRNA's universal approach to common nonsense mutations provides a compelling "reason to believe" backed by preclinical and now in vivo data. She highlights the company’s plan to utilize basket trials, a strategy common in oncology, to simultaneously its therapies simultaneously across multiple rare diseases sharing common mutations —not only optimizing development, but also unlocking value in ultra-rare diseases often overlooked due to small individual patient populations.

  7. Ep. 254, Chapter 1: Michelle Werner, Alltrna 7/11/2025

    Life Science Leader Chief Editor Ben Comer, joined by Advancing RNA Editorial and Community Director Anna Rose Welch, interviews Michelle Werner, CEO of Alltrna, which develops transfer RNA (tRNA) oligonucleotide therapies. Werner joined Alltrna following her son's diagnosis with Duchenne muscular dystrophy in 2020. She was drawn to the company’s unique platform, which aims to use a single engineered tRNA to address numerous different diseases, a significant departure from the one-disease-at-a-time approach of modalities like gene therapy. Werner also discusses the transition from a commercial role to leading a biotech startup, particularly the challenges of fundraising and managing a team of scientists.

  8. Ep. 253, Chapter 4: Infectious Disease + Oncology with Mark Eisner, MD 7/11/2025

    Vir Biotechnology's oncology strategy centers on overcoming the toxicity of unmasked T-cell engagers in solid tumors using the company’s PRO-XTEN™ masking platform. Vir currently has three clinical-stage programs: a HER2-directed T-cell engager for various HER2-positive tumors, a PSMA-targeted program for metastatic castration-resistant prostate cancer, and an EGFR-targeting TCE for multiple tumor types. Dr. Eisner stresses that masking technology allows for effective tumor killing with minimal toxicity. In 2025 and 2026, Vir's top goals include pivotal trials for hepatitis delta, continuing dose escalation for HER2 and PSMA programs, initiating the EGFR program, and identifying a partner for global development of the company’s hepatitis B functional cure program.

  9. Ep. 253, Chapter 3: Addressing Hepatitis Delta with Mark Eisner, MD 7/11/2025

    Hepatitis delta, a rare but severe liver disease that progresses rapidly, requires co-infection with hepatitis B. Hepatitis delta currently has no approved therapies in the U.S., though bulevirtide is used in Europe despite limited efficacy. In partnership with Alnylam Pharmaceuticals, Vir is poised to begin a Phase 3 trial for its combination regimen of tobevibart and elebsiran, which researchers believe can achieve complete viral suppression in most patients. Dr. Eisner emphasizes that partnerships are vital for biopharma companies like Vir to leverage scientific innovation and access global commercialization capabilities.

  10. Ep. 253, Chapter 2: The Art Of The Biotech Pivot with Mark Eisner, MD 7/11/2025

    Dr. Eisner explains how Vir’s Technology’s pivot from infectious disease to include oncology is more substantial than a large company reshuffling its portfolio, highlighting the thematic connection through the immune system and the foundational role of antibody engineering at Vir. He also details Vir's two distinct platforms: the dAIsY™ platform, an AI-driven tool for accelerating and optimizing antibody engineering, and the PRO-XTEN™ platform, a masking technology for T-cell engagers designed to improve efficacy and safety. Both platforms are considered complementary and are continuously refined.